Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Short Interest Up 5.6% in September

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) saw a large increase in short interest during the month of September. As of September 15th, there was short interest totalling 478,300 shares, an increase of 5.6% from the August 31st total of 452,800 shares. Approximately 3.5% of the shares of the company are short sold. Based on an average daily volume of 61,400 shares, the short-interest ratio is presently 7.8 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Acurx Pharmaceuticals in a report on Monday, August 12th.

Institutional Trading of Acurx Pharmaceuticals

A hedge fund recently bought a new stake in Acurx Pharmaceuticals stock. NBC Securities Inc. bought a new stake in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) in the 1st quarter, according to its most recent filing with the SEC. The fund bought 14,000 shares of the company’s stock, valued at approximately $34,000. NBC Securities Inc. owned 0.09% of Acurx Pharmaceuticals at the end of the most recent reporting period. 11.53% of the stock is currently owned by institutional investors.

Acurx Pharmaceuticals Stock Performance

Shares of ACXP stock opened at $1.92 on Wednesday. Acurx Pharmaceuticals has a fifty-two week low of $1.17 and a fifty-two week high of $8.82. The firm has a market capitalization of $30.42 million, a PE ratio of -1.63 and a beta of -1.72. The stock’s 50-day simple moving average is $2.06 and its 200-day simple moving average is $2.16.

Acurx Pharmaceuticals (NASDAQ:ACXP) last issued its quarterly earnings results on Friday, August 9th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.02. During the same quarter last year, the company posted ($0.28) earnings per share. Sell-side analysts forecast that Acurx Pharmaceuticals will post -0.98 earnings per share for the current year.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.